Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000693943 | SCV000822367 | likely benign | Pityriasis rubra pilaris; Psoriasis 2 | 2024-01-25 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV001507909 | SCV001713749 | uncertain significance | not provided | 2021-05-07 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV002263936 | SCV002542453 | uncertain significance | Autoinflammatory syndrome | 2019-11-01 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001507909 | SCV004146303 | likely benign | not provided | 2022-11-01 | criteria provided, single submitter | clinical testing | CARD14: BP4 |
Prevention |
RCV003945716 | SCV004760453 | likely benign | CARD14-related disorder | 2023-02-20 | criteria provided, single submitter | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |
Genome Diagnostics Laboratory, |
RCV001507909 | SCV001931632 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV001507909 | SCV001963813 | likely benign | not provided | no assertion criteria provided | clinical testing |